Although tumour PD-L1 (CD274) expression had been used as a predictive biomarker in checkpoint immunotherapy targeting the PD1/PD-L1 axis in various cancers, the regulation of PD-L1 (CD274) expression is unclear. Yes-associated protein 
cancers including non-small-cell lung cancer, melanoma, renal cell carcinoma and Hodgkin lymphoma. [6] [7] [8] [9] [10] Recently, PD-1/PD-L1 inhibitors were also used to treat patients with advanced MPM, and several clinical trials are ongoing. 11, 12 Tumour PD-L1 expression has been used as a predictive biomarker for PD-1/PD-L1 inhibitors. 6, 12, 13 However, how the tumour PD-L1 expression is regulated in cancer cells is not obvious.
Yes-associated protein (YAP) is a key oncogenic mediator in the
Hippo signalling pathway and promotes tumorigenesis, invasion, metastasis and drug resistance in several cancers. [14] [15] [16] [17] [18] YAP has also been identified in human MPM and is correlated with tumorigenesis and cancer development, suggesting YAP is a therapeutic target for treating advanced unresectable MPM. [19] [20] [21] YAP regulates tumourassociated immune cells such as myeloid-derived suppressor cells (MDSCs) and tumour-associated macrophages (TAMs). 22, 23 YAP may be involved in the immune checkpoint. 22, 23 Here, we sought to investigate whether YAP is involved in the regulation of PD-L1 expression of human MPM and whether inhibition of YAP downregulates PD-L1 expression in human MPM.
| MATERIALS AND METHODS

| Cell lines and cell culture
Human mesothelioma cell lines H2052, 211H, H28 and H2452
were purchased from American Type Culture Collections (ATCC, Manassas, VA, USA), and H290 and MS-1 were purchased from NIH (Frederick, MD, USA). Human non-small-cell lung cancer cell line A549 was purchased from American Type Culture Collections (ATCC). Human normal mesothelial cell line LP-9 was purchased from the Cell Culture Core Facility at Harvard University (Boston, MA, USA). The 5 mesothelioma cell lines and A549 cells were maintained in RPMI-1640 medium supplemented with 10% heatinactivated foetal bovine serum (FBS) and penicillin (100 IU/mL).
LP-9 was maintained in M199 supplemented with 15% heat-inactivated FBS, 10 ng/mL EGF, 0.4 lg/mL hydrocortisone and penicillin (100 IU/mL). All cell lines were incubated at 37°C in a humid incubator with 5% CO 2 .
| Tissue samples and immunohistochemistry
Fresh primary MPM and adjacent normal pleural tissues were obtained from 70 patients with MPM whose primary tumours were surgically resected. There are few exception normal pleural tissues used as normal control from non-tumour patients on the same array. 
| Western blot analysis
The total amount of protein for each sample was 20 lg. Biosystems 7000 sequence detection system (Applied Biosystems).
Relative Quantification Software (Applied Biosystems) was used for mRNA expression analysis.
| Luciferase reporter assay
The 89 GTIIC-luciferase plasmid (Addgene) and Renilla luciferase 
| ChIP assay
Fragmented chromatin from H2052 cells was incubated with antiIgG (negative control), anti-YAP and anti-POL-II (positive control).
Recruited DNA was subjected to PCR using the primers for distal enhancer regions of PD-L1, and PCR products were electrophoresed in agarose gel. The ChIP assay was conducted using the Chromatin 
| Concurrent expression of YAP and PD-L1 in mesothelioma tumours
We next used immunohistochemistry to investigate the relationship between YAP and PD-L1 expression in tissue samples from 70 patients with MPM. The YAP and PD-L1 staining were negative in normal pleural tissues ( Figure 6A ,B,I,J). PD-L1 staining in the cytoplasm was negative (À) in 28.6%, weak (+) in 34.2% and moderate to strong (++/+++) in 37.2% (Figure 6C ,E,G,K,M,O, Table 1 ). YAP staining in the nucleus was negative (À) in 15.7% of the samples, weak (+) in 30.0% and moderate to strong (++/+++) in 54.3% ( Figure 6D ,F,H,L,N,P, Table 1 ). The relationship between YAP and PD-L1 was analysed, and we found that moderate to strong PD-L1 expression was concurrent with moderate and strong nuclear YAP staining (P < .05, chi-square test; Figure 6Q ). 
| DISCUSSION
